AEZS

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Aeterna Zentaris (AEZS – Research Report) today and set a price target of $2.00. The company's shares closed last Thursday at $0.35, close to its 52-week low of $0.29. According to TipRanks.com, Selvaraju 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -33.0% and a 17.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Oncternal Therapeutics, and Oramed Pharmaceuticals. Currently, the analyst consensus on Aeterna Zentaris is a Moderate Buy with an average price target of $2.00.
https://www.tipranks.com/news/blurbs/h-c-wainwright-reiterates-their-buy-rating-on-aeterna-zentaris-aezs?utm_source=advfn.com&utm_medium=referral